Sitagliptin Market Size, Share & Industry Analysis, By Product (Januvia, Janumet, and Others), By Formulation (Immediate-Release Tablets, Extended-Release Tablets, and Others), By Disease Indication (Diabetes and Others), By Age Group (Pediatric and Adults), By Type (Branded and Generic), By Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2026-2034

The global sitagliptin market size was valued at USD 3.67 billion in 2025. The market is projected to grow from USD 3.90 billion in 2026 to USD 5.83 billion by 2034, exhibiting a CAGR of 5.14% during the forecast period. Asia Pacific dominated the sitagliptin market with a market share of 34.6% in 2025.

The global market is growing steadily due to the rising burden of type 2 diabetes and the continued demand for anti-diabetic medicines for long-term use. Sitagliptin is a DPP-4 inhibitor used to improve glycemic control in adults with type 2 diabetes, either as a standalone therapy or in combination with metformin. The market is supported by established branded products such as Januvia, Janumet, and Janumet XR, while patent expiries and generic launches are widening access in price-sensitive markets. At the same time, new formulations and distribution partnerships are helping companies improve patient reach, adherence, and product availability across developed and emerging regions.

• In July 2025, Azurity Pharmaceuticals launched BRYNOVIN, an oral liquid sitagliptin formulation for adults with type 2 diabetes. The launch supports the market by addressing patients who may have difficulty swallowing tablets and by expanding formulation options within sitagliptin therapy.

Furthermore, Merck & Co., Inc., Zydus Lifesciences Ltd., and Teva Pharmaceutical Industries Ltd. held the majority of the market share due to their broad portfolios.

Download Free sample to learn more about this report.

Sitagliptin Market Key Takeaways

Global Market Size & Forecast

• 2025 Market Size: USD 3.67 billion
• 2026 Market Size: USD 3.90 billion
• 2034 Forecast Market Size: USD 5.83 billion
• CAGR: 5.14% (2026–2034)

Market Share

• Asia Pacific dominated the market with a 34.6% share in 2025.
• The others segment is projected to grow at a 11.50% CAGR during the forecast period.
• The diabetes segment held the largest market share by disease indication in 2025.

Key Regional Highlights

Asia Pacific

Asia Pacific generated USD 1.18 billion in 2024 and is projected to reach USD 1.41 billion in 2026, maintaining its leading position.

North America

North America generated USD 1.27 billion in 2025, maintaining its second-largest regional position.

Europe

Europe is projected to reach USD 0.73 billion by 2026, growing at a 1.81% rate.

U.S.

U.S. market is projected to reach USD 1.18 billion by 2026.

Japan

Japan market is projected to reach USD 0.19 billion by 2026.

Read More

SITAGLIPTIN MARKET TRENDS

Growing Shift Toward Generic Sitagliptin to Improve Diabetes Treatment Affordability

A prominent trend witnessed in the market is the wider availability of generic drugs, as branded DPP-4 inhibitor products face patent expiry and loss of exclusivity in key markets. This shift is important as type 2 diabetes requires long-term treatment, and lower-cost generic versions can improve patient access, especially in price-sensitive healthcare systems. As more companies launch sitagliptin and sitagliptin-metformin products, competition is expected to increase, which may reduce treatment costs and expand prescription volumes. At the same time, branded players are focusing on distribution partnerships and portfolio access strategies to protect market presence in high-volume diabetes markets.

• In June 2026, Apotex launched sitagliptin tablets and sitagliptin and metformin hydrochloride tablets in the U.S., both eligible for 180-day shared exclusivity. These launches expand its portfolio of treatment options for adults living with type 2 diabetes mellitus.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Prevalence of Type 2 Diabetes to Drive Demand for Sitagliptin-Based Therapies

The global market is expected to grow as the number of adults living with type 2 diabetes continues to rise across both developed and emerging economies. This growing patient pool increases the need for long-term glucose-lowering therapies, especially oral medicines that are easy to prescribe and convenient for daily use. As sitagliptin is used to improve glycemic control in adults with type 2 diabetes, the rising diagnosis and treatment rate directly supports demand for both branded and generic sitagliptin-based products. In addition, the long-term nature of diabetes management creates recurring prescription demand, supporting market growth over the forecast period.

• For instance, according to the IDF Diabetes Atlas, in 2024, around 589 million adults aged 20–79 years were living with diabetes globally, representing 11.1% of the adult population.

MARKET RESTRAINTS

Increasing Generic Competition and Shift Toward Newer Diabetes Drug Classes to Limit Market Value Growth

A factor restraining the global sitagliptin market growth is increasing pressure, as the product class moves from a branded, high-value market toward a more price-competitive generic market. Patent expiry of key sitagliptin brands such as Januvia and Janumet has encouraged generic entry in several markets, which improves affordability but reduces average selling prices and limits revenue growth for branded manufacturers. As a result, sitagliptin may continue to retain prescription demand among suitable type 2 diabetes patients. Still, its overall market value growth is expected to remain restrained by price erosion and stronger competition from newer treatment options.

MARKET OPPORTUNITIES

Expansion of Combination Sitagliptin Products in Emerging Markets to Create Growth Opportunities

The global market is expected to gain growth opportunities from the fixed-dose combination products, especially in emerging markets with a large diabetes patient base. Combination products such as sitagliptin with metformin create growth opportunities as they simplify treatment, reduce pill burden, and support better adherence among adults needing multi-drug glycemic control. As branded products face patent expiry, generic manufacturers and distribution partners can expand sitagliptin availability across retail, hospital, and pharmacy networks, creating volume-led growth despite price competition.

• In June 2025, Abbott collaborated with Merck & Co., Inc. to distribute the company’s oral anti-diabetic medicines in India, including sitagliptin, sitagliptin/metformin combination, and the extended-release combination. Such developments are supporting growth opportunities for sitagliptin-based products in a high-burden diabetes market.

MARKET CHALLENGES

Balancing Price Erosion and Volume Growth Amid Generic Sitagliptin Expansion

The global market is expected to face a key challenge in maintaining value growth as generic products expand across major markets. Generic entry can increase patient access and prescription volumes, but it also reduces average selling prices, which can weaken overall revenue growth for branded sitagliptin products. This creates a difficult balance for manufacturers, as higher unit demand may not fully offset the decline in product pricing after loss of exclusivity. In addition, companies operating in this market must manage competition from multiple generic suppliers while also responding to stronger treatment preference for newer diabetes drug classes. As a result, the market may continue to grow in volume, but revenue growth is likely to remain under pressure during the forecast period.

Segmentation Analysis

By Product

Strong Brand Recognition and Early Market Entry Supported Januvia’s Dominance

Based on the product, the market is segmented into Januvia, Janumet, and others.

Januvia dominated the product segment in 2025 as it was one of the earliest and most established sitagliptin brands used for type 2 diabetes management. Its long presence in the market helped build strong physician familiarity, patient trust, and wide prescription acceptance. Also, it offers flexibility for physicians to prescribe it alone or with other anti-diabetic medicines depending on the patient's needs. This helped the product maintain a strong position, especially among patients who require DPP-4 inhibitor therapy but may not need a fixed-dose combination. Strategic collaboration with other operating entities in the market to expand access further drives the segmental growth.

• In December 2025, Merck & Co., Inc. collaborated with the U.S. administration to ensure its prescription medicines are both accessible and affordable for Americans. This agreement includes JANUVIA, JANUMET, and JANUMET XR. It enables the company to develop and deliver life-changing medicines and ensure Americans have access to those innovations at lower costs.

The others segment is projected to grow at a CAGR of 14.83% during the global sitagliptin market forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Formulation

High Prescribing Convenience and Broad Availability Supported Immediate-Release Tablets Segment Dominance

By formulation, the market is segmented into immediate-release tablets, extended-release tablets, and others.

Immediate-release tablets dominated the formulation segment in 2025. The segment dominated as they are the most commonly used and widely available sitagliptin dosage forms. These tablets are convenient for daily diabetes management and are easier for physicians to prescribe across a broad adult patient population. Their simpler formulation also supports wider manufacturing by branded and generic companies, which improves availability across hospital, retail, and pharmacy channels. As a result, immediate-release tablets remained the preferred formulation due to ease of use, established prescribing habits, and broader product availability.

• In December 2023, Lupin received tentative U.S. FDA approval for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths, a generic equivalent of Januvia tablets, supporting the continued relevance of tablet-based sitagliptin therapy.

The others segment is anticipated to grow at a CAGR of 11.50% over the forecast period.

By Disease Indication

Rising Type 2 Diabetes Treatment Needs Strengthened Diabetes Segment Dominance

By disease indication, the market is segmented into diabetes and others.

The diabetes segment held the largest share in the market based on disease indication. Sitagliptin is primarily indicated for improving glycemic control in patients with type 2 diabetes. The segment benefits from the large and continuously treated patient base, as diabetes requires long-term therapy and regular medication use. Since sitagliptin helps manage blood glucose and is often used when patients need additional control beyond lifestyle changes or metformin, its demand remains closely linked to diabetes treatment volumes. This direct therapeutic relevance made diabetes the leading indication in the market.

• In July 2022, Glenmark Pharmaceuticals launched sitagliptin and its fixed-dose combinations under the SITAZIT brand in India for adults with type 2 diabetes, stating that the products were introduced to improve affordability and access for diabetes patients.

The others segment is anticipated to grow at a CAGR of 10.02% over the forecast period.

By Age Group

Adult Type 2 Diabetes Patient Pool Supported Adult Segment Dominance

By age group, the market is segmented into pediatric and adults.

The adult segment dominated the sitagliptin market share based on age group. Sitagliptin-based therapies are mainly used for type 2 diabetes, which is more common in the adult population. Most approved sitagliptin products are positioned for adult patients, and prescribing is largely concentrated among adults requiring long-term glycemic control. The need for convenient oral medicines, low treatment complexity, and continuous disease management further supports higher sitagliptin use among adults compared to pediatric patients. Therefore, the adult segment held the dominant share due to both disease prevalence and product indication alignment.

• In October 2023, Zydus Lifesciences announced U.S. FDA approval for ZITUVIO, a sitagliptin tablet indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The pediatric segment is anticipated to grow at a CAGR of 9.60% over the forecast period.

By Type

Established Innovator Products and Physician Trust Supported Branded Segment Dominance

By type, the market is segmented into branded and generic.

Branded products dominated the type segment due to strong market presence of established sitagliptin brands such as Januvia and Janumet. These products benefited from earlier market entry, clinical familiarity, strong distribution networks, and high physician confidence built over years of use. In many countries, branded sitagliptin products also maintained a strong position before full-scale generic substitution increased. As a result, branded products accounted for a larger value share, even though generic competition is gradually increasing in several markets.

• In July 2022, Zydus Lifesciences Ltd. launched the molecule Sitagliptin in India under the brand names Sitaglyn and Siglyn to address Type 2 diabetes in India.

The generic segment is anticipated to grow at a CAGR of 14.38% over the forecast period.

By Distribution Channel

Chronic Prescription Refills and Easy Patient Access Supported Drug Stores and Retail Pharmacies Segment Dominance

On the basis of the distribution channel, the market is segmented into drug stores & retail pharmacies, hospital pharmacies, online pharmacies, and others.

In 2025, drug stores and retail pharmacies dominated the distribution channel segment as sitagliptin is mainly used for long-term outpatient diabetes management. Patients with type 2 diabetes require regular prescription refills, making retail pharmacies the most convenient and frequently used purchase channels. Retail pharmacy networks also support better availability of branded, generic, and combination sitagliptin products, especially in urban and semi-urban markets. This regular refill pattern and easy accessibility helped drug stores and retail pharmacies capture the leading share in the market.

• In January 2025, Zydus collaborated with CVS Caremark to add Zituvio, Zituvimet, and Zituvimet XR to its template formulary, supporting pharmacy-based access to sitagliptin and sitagliptin-metformin products for adults with type 2 diabetes. Zituvio and combination products are included. These three NDAs of Sitagliptin (base) and the combination franchise have been approved by the USFDA earlier through the 505(b)(2) route.

In addition, the online pharmacies segment is projected to grow at a CAGR of 10.62% over the forecast period.

Sitagliptin Market Regional Outlook

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

Asia Pacific

To get more information on the regional analysis of this market, Download Free sample

Asia Pacific dominated the market in 2024 with a valuation of USD 1.18 billion and maintained its dominant position in 2025. Further, the region is estimated to reach USD 1.41 billion in 2026. Asia Pacific is growing rapidly due to its large diabetes patient pool, especially in countries such as India, China, and Japan. Rising diagnosis rates and increasing access to affordable generics are expanding treatment volumes.

Japan Sitagliptin Market

The Japanese market in 2026 is estimated at around USD 0.19 billion, accounting for approximately 4.81% of the global market.

China Sitagliptin Market

China's market is projected to be among the largest worldwide, with 2026 revenues estimated at around USD 0.46 billion, accounting for approximately 11.91% of global sales.

India Sitagliptin Market

The Indian market size is estimated at around USD 0.32 billion in 2026, accounting for roughly 8.31% of global revenue.

North America

North America held the second-largest share in 2024 at USD 1.25 billion and maintained its leading position in 2025 at USD 1.27 billion. The market is growing in North America due to the high prevalence of type 2 diabetes, robust healthcare infrastructure, and strong use of prescription-based oral anti-diabetic therapies. Wide availability of branded and generic sitagliptin products supports continuous patient access. Strong retail pharmacy networks and insurance coverage further support long-term prescription refills.

U.S. Sitagliptin Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 1.18 billion in 2026, accounting for roughly 30.33% of the global market.

Europe

Europe is projected to grow at 1.81% over the coming years, the third-highest among all regions, and reach a valuation of USD 0.73 billion by 2026. Europe is witnessing growth due to the rising aging population and increasing diabetes management needs. The region has strong clinical adoption of oral diabetes therapies, including DPP-4 inhibitors, for suitable patient groups. Generic availability is also improving affordability and supporting wider use across public healthcare systems.

U.K. Sitagliptin Market

The U.K. market size is estimated at USD 0.12 billion in 2026, accounting for roughly 3.05% of the global market.

Germany Sitagliptin Market

Germany's market is projected to reach approximately USD 0.15 billion in 2026, equivalent to around 3.86% of the global market.

Latin America and the Middle East & Africa

The Latin America region is expected to witness growth in this market during the forecast period and is estimated to reach a valuation of USD 0.26 billion by 2026. The market is growing in Latin America due to increasing diabetes prevalence and improving access to chronic disease medicines.

Further, retail pharmacy expansion and broader availability of generic oral anti-diabetic drugs are supporting patient access. In the Middle East & Africa, the GCC is set to reach USD 0.09 billion in 2026.

South Africa Sitagliptin Market

The South African market is projected to reach approximately USD 0.04 billion by 2026, accounting for roughly 0.91% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Regulatory Approval and New Product Developments among Key Companies to Strengthen Market Growth

The global sitagliptin market is moderately consolidated, with Merck & Co., Inc maintaining a leading position due to the strong brand presence of Januvia, Janumet, and Janumet XR. However, the market is gradually becoming more competitive as patent expiries are opening opportunities for generic manufacturers to launch lower-cost sitagliptin and sitagliptin-metformin products. Key companies are strengthening their presence through product approvals, launches, distribution partnerships, and expanded generic portfolios. These companies are focusing on improving affordability, increasing pharmacy access, and expanding the availability of both single-agent and fixed-dose combination sitagliptin therapies.

• In October 2023, Zydus Lifesciences announced U.S. FDA approval for ZITUVIO, a sitagliptin tablet indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Among these players, Zydus Lifesciences, Apotex, Teva, Lupin, Glenmark, and Azurity Pharmaceuticals are actively involved in recent product development and commercialization activities. At the same time, generic manufacturers are expected to gain share during the forecast period as healthcare systems and patients increasingly prefer affordable oral diabetes therapies. This shift is likely to make the market more volume-driven, with competition centered on pricing, formulation convenience, product availability, and distribution strength.

LIST OF KEY SITAGLIPTIN COMPANIES PROFILED

• Merck & Co., Inc. (U.S.)
• Zydus Lifesciences Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Apotex Corp. (Canada)
• Lupin Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Glenmark Pharmaceuticals Ltd. (India)
• Reddy’s Laboratories Ltd. (India)
• Aurobindo Pharma Ltd. (India)
• Biocon Ltd. (India)

KEY INDUSTRY DEVELOPMENTS

• June 2026: Apotex announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both eligible for 180-day shared exclusivity. The company stated that these launches expand its portfolio of treatment options for adults living with type 2 diabetes mellitus.
• August 2025: Biocon Pharma Limited received tentative approval from the U.S. FDA for its ANDA for Sitagliptin Tablets USP, in 25 mg, 50 mg, and 100 mg strengths. Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• January 2024: Jamjoom Pharma collaborated with Merck & Co., Inc. for the production of sitagliptin phosphate, a medication for the treatment of type 2 diabetes. The collaboration aimed to integrate and enhance health and pharmaceutical security and development in Saudi Arabia.
• September 2022: Celix Pharma launched Sitagliptin 25mg, 50mg and 100mg film-coated tablets on loss of exclusivity in the U.K. Sitagliptin belongs to a class of drugs called DPP4 inhibitors and is indicated for treatment of Type 2 diabetes, either as a monotherapy or in combination with metformin and/or a sulphonylurea.
• October 2021: Codexis, Inc. collaborated with Almelo Private, Ltd., and RC2 Pharma Connect, LLC, to license and manufacture for internal use a Codexis’ proprietary enzyme used in the manufacturing process for sitagliptin, a leading API in the treatment of diabetes.

REPORT COVERAGE

The global sitagliptin market report provides a detailed assessment of all market segments, highlighting key drivers, trends, opportunities, restraints, and challenges shaping industry growth. It also covers the rising burden of type 2 diabetes, increasing use of oral anti-diabetic therapies, patent expiry impact, generic competition, and changing treatment preferences across major regions. The report also provides global market analysis on branded and generic product performance, formulation trends, distribution channel dynamics, and demand patterns across adult and pediatric patient groups. It includes regional market analysis, competitive landscape, recent company developments, product launches, strategic partnerships, and comprehensive profiles of leading companies operating in the market.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation